This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspira (AWH) delivered earnings and revenue surprises of -1,360% and 0.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
by Zacks Equity Research
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Trevena (TRVN) a New Buy Stock
by Zacks Equity Research
Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 6% and 15.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Trevena (TRVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and 100.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) to Begin Clinical Study on Pain Candidate
by Zacks Equity Research
Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.
Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Trevena (TRVN) delivered earnings and revenue surprises of -12.50% and -85.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
by Zacks Equity Research
Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.